NewsGlobeNewswire
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
· Published
Article summary
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…